anastrozole

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Aromatase inhibitor

Related drugs:

‹

›

HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1
ER negative	Breast Cancer	ER negative	Breast Cancer	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant + anastrozole Sensitive: A2 - Guideline fulvestrant + anastrozole Sensitive : A2	fulvestrant + anastrozole Sensitive: A2 - Guideline fulvestrant + anastrozole Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2
ER positive + PGR positive	HER2 Negative Breast Cancer	ER positive + PGR positive	HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2
PGR positive	HER2 Negative Breast Cancer	PGR positive	HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2
PGR positive	Uterine Cancer	PGR positive	Uterine Cancer	anastrozole Sensitive: C2 – Inclusion Criteria anastrozole Sensitive : C2	anastrozole Sensitive: C2 – Inclusion Criteria anastrozole Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	anastrozole Sensitive: C2 – Inclusion Criteria anastrozole Sensitive : C2	anastrozole Sensitive: C2 – Inclusion Criteria anastrozole Sensitive : C2
TK1 elevation	Hormone Receptor Positive Breast Cancer	TK1 elevation	Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials fulvestrant + anastrozole Sensitive : C3	fulvestrant + anastrozole Sensitive: C3 – Early Trials fulvestrant + anastrozole Sensitive : C3
BRCA2 mutation	Hormone Receptor Positive Breast Cancer	BRCA2 mutation	Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Resistant: C3 – Early Trials fulvestrant + anastrozole Resistant : C3	fulvestrant + anastrozole Resistant: C3 – Early Trials fulvestrant + anastrozole Resistant : C3
BRCA1 mutation	Hormone Receptor Positive Breast Cancer	BRCA1 mutation	Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Resistant: C3 – Early Trials fulvestrant + anastrozole Resistant : C3	fulvestrant + anastrozole Resistant: C3 – Early Trials fulvestrant + anastrozole Resistant : C3
PIK3CA mutation	Hormone Receptor Positive Breast Cancer	PIK3CA mutation	Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials fulvestrant + anastrozole Sensitive : C3	fulvestrant + anastrozole Sensitive: C3 – Early Trials fulvestrant + anastrozole Sensitive : C3
ER positive + PGR positive	Uterine Cancer	ER positive + PGR positive	Uterine Cancer	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
ER positive + PGR positive	Uterine Corpus Leiomyosarcoma	ER positive + PGR positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
ER positive	Uterine Cancer	ER positive	Uterine Cancer	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
PLK1 overexpression	Estrogen Receptor Positive Breast Cancer	PLK1 overexpression	Estrogen Receptor Positive Breast Cancer	anastrozole Sensitive: D – Preclinical anastrozole Sensitive : D	anastrozole Sensitive: D – Preclinical anastrozole Sensitive : D
CSMD1 overexpression	Breast Cancer	CSMD1 overexpression	Breast Cancer	anastrozole Sensitive: D – Preclinical anastrozole Sensitive : D	anastrozole Sensitive: D – Preclinical anastrozole Sensitive : D

anastrozole

Associations
(23)

Associations
(23)

anastrozole

Associations(23)

Associations(23)

Associations
(23)

Associations
(23)